Gecacitinib Hydrochloride is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) and Yujun DONG (1). Registered phases: Phase 1/2 and Phase 1. Conditions studied include Non-small Cell Lung Cancer; Healthy; Chronic Graft Versus Host Disease.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06903377 | Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer |
Phase 1/2 | Recruiting |
| NCT07012304 | Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy (ClinicalTrials.gov ↗) Chronic Graft Versus Host Disease |
Phase 1/2 | Recruiting |
| NCT07565597 | A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. (ClinicalTrials.gov ↗) Healthy |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-small Cell Lung Cancer | 1 |
| Healthy | 1 |
| Chronic Graft Versus Host Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2 |
| Yujun DONG | 1 |
| Register | Gecacitinib Hydrochloride trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gecacitinib Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gecacitinib Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.